Shingles Vaccination and Reduced Dementia Risk

This study examines whether receiving the live-attenuated herpes zoster vaccine reduces the risk of developing dementia among older adults in Canada. Researchers utilized a natural experiment in Ontario, where government funding for the vaccine was strictly determined by specific date-of-birth eligibility thresholds. By comparing individuals born just days apart, the authors isolated the vaccine's impact from other lifestyle factors and found that eligibility led to a significant decrease in new dementia diagnoses over a five-year period. These protective effects were notably more pronounced in female participants than in males. The findings suggest that targeting neurotropic herpesviruses through immunization may be a viable strategy for maintaining neuroimmune health and delaying cognitive decline. This research provides strong evidence for a causal relationship, supporting the theory that viral reactivation plays a role in the progression of brain diseases.